Asclepion
Dermablate® Er:YAG COOL Laser
State-of-the-Art Er:YAG COOL Laser®
Technology Overview
The MEDEX CO₂ Fractional Laser System features a patented dual-mode scanning technology combining Hyper-Scan Fractional and Galvo Scanner modes. The Hyper-Scan Fractional mode delivers a spot size of 1.3mm with adjustable depth from 10-300μm and density from 0.2-1.6mm, ideal for broad area resurfacing. The Galvo Scanner mode provides ultra-precise delivery with a 0.12mm spot size and depth range of 100-3,500μm (up to 4,000μm), enabling deep tissue remodeling. Clinical studies demonstrate up to 400% increase in collagen production at 6 months post-treatment, making it the gold standard for deep skin remodeling in acne scar revision and photoaging treatment.
Clinical illustration: How Hyper-Scan technology targets different skin tissue layers
Key Applications & Indications
Acne Scars
Traumatic Scars
Photoaging
Skin Texture Irregularities
Benign Skin Lesions
Wrinkles
Skin Laxity
Clinical Advantages
Patented Scanning Technology for precision delivery
Adjustable Density & Depth suitable for Fitzpatrick III-V skin types
Dual-Mode Function (Hyper-Scan + Galvo Scanner)
Proven Collagen Remodeling with up to 400% increase at 6 months
Comprehensive treatment for moderate-severe conditions
Technical Specifications
| Parameter | Specification |
|---|---|
| Certification | MDA Certified |
| Collagen Increase | Up to 400% at 6 months |
| Galvo Scanner Depth | 100-3,500μm (up to 4,000μm) |
| Galvo Scanner Spot Size | 0.12mm |
| Hyper-Scan Density | 0.2-1.6mm |
| Hyper-Scan Depth | 10-300μm |
| Hyper-Scan Spot Size | 1.3mm |
| Laser Type | CO₂ (Carbon Dioxide) Fractional |
| Recovery Period | 7-10 days |
Ideal Patient Profile
Patients with moderate-to-severe acne scarring, significant photoaging, or those seeking comprehensive 'one and done' treatments. Suitable for patients who can accept 7-10 days of downtime for superior long-term results. The adjustable parameters make it appropriate for Fitzpatrick skin types III-V, which is particularly relevant for the Southeast Asian patient demographic.